SCLN Share Price

Open 11.02 Change Price %
High 11.05 1 Day 0.05 0.45
Low 11.00 1 Week 0.00 0.00
Close 11.05 1 Month 0.15 1.38
Volume 199282 1 Year 0.75 7.28
52 Week High 11.43
52 Week Low 8.55
SCLN Important Levels
Resistance 2 11.10
Resistance 1 11.08
Pivot 11.03
Support 1 11.02
Support 2 11.00
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.17 21.43%
FNFG 10.18 -0.20%
QQQ 141.33 -2.04%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
VRTA 4.50 38.46%
SPEX 1.81 30.22%
ADAT 1.42 26.79%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NEXS 0.10 25.00%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)

SCLN Technical Analysis 5
As on 17th Aug 2017 SCLN Share Price closed @ 11.05 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 10.16 & Strong Buy for SHORT-TERM with Stoploss of 10.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCLN Target for August
1st Target up-side 11
2nd Target up-side 11.04
3rd Target up-side 11.08
1st Target down-side 10.9
2nd Target down-side 10.86
3rd Target down-side 10.82
SCLN Other Details
Segment EQ
Market Capital 307798784.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sciclone.com
SCLN Address
SCLN
950 Tower Lane
Suite 900
Foster City, CA 94404
United States
Phone: 650-358-3456
Fax: 650-358-3469
SCLN Latest News
Interactive Technical Analysis Chart SciClone Pharmaceuticals, Inc. ( SCLN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SciClone Pharmaceuticals, Inc.
SCLN Business Profile
SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company�s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone�s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc.